Forest/PAION Desmoteplase Scare Is Brief: Trial Resumes After Two-Day Hold
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A pre-Halloween scare for PAION/Forest's vampire bat protein-based stroke therapy desmoteplase resolved quickly when a halt on patient recruitment in a Phase IIb/III trial was lifted within two days of the announcement of a possible safety signal